Jeff Ryckman, Associate Professor of Radiation Oncology at WVU Medicine Camden Clark Medical Center, shared on X:
“DeLLphi-305 (LBA3): tarlatamab + durvalumab vs durvalumab maintenance in ES-SCLC without progression after durvalumab + platinum-etoposide.
OS HR 0.42 (CI 0.32-0.54); 12-mo OS 79% vs 53%, median OS 21 vs 13 mo.
Impressive OS signal.
Was thoracic consolidation RT allowed?
The abstract doesn’t say.
If so, would be interested to see fractionation/dosing schemes and how RT was interdigitated.”
You can also read: DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
